March 4 (Reuters) - Dermata Therapeutics Inc DRMA.O:
DERMATA ANNOUNCES THAT LAST PATIENT COMPLETES LAST VISIT IN PIVOTAL XYNGARI™ PHASE 3 STAR-1 CLINICAL TRIAL FOR ACNE
DERMATA THERAPEUTICS INC - TOPLINE DATA EXPECTED BY END OF MARCH 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.